Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 2. Biomarkers of exposure

Michael W Ogden, Kristin M Marano, Bobbette A Jones, Walter T Morgan, Mitchell F Stiles, Michael W Ogden, Kristin M Marano, Bobbette A Jones, Walter T Morgan, Mitchell F Stiles

Abstract

A randomized, multi-center study of adult cigarette smokers switched to tobacco-heating cigarettes, snus or ultra-low machine yield tobacco-burning cigarettes (50/group) was conducted, and subjects' experience with the products was followed for 24 weeks. Differences in biomarkers of tobacco exposure between smokers and never smokers at baseline and among groups relative to each other and over time were assessed. Results indicated reduced exposure to many potentially harmful constituents found in cigarette smoke following product switching. Findings support differences in exposure from the use of various tobacco products and are relevant to the understanding of a risk continuum among tobacco products (ClinicalTrials.gov Identifier: NCT02061917).

Keywords: Mouth level exposure; multi-center randomized study; risk continuum; tobacco and tobacco smoke constituents; yield-in-use.

Figures

Figure 1.
Figure 1.
Percent change in urinary NICEq over time in smokers switched to tobacco-heating cigarettes (TH), snus or ultra-low machine yield tobacco-burning cigarettes (TB). *Statistically significant reduction (p<0.05) from week 0.
Figure 2.
Figure 2.
Percent change in urinary total NNAL, a marker of NNK exposure, over time in smokers switched to tobacco-heating cigarettes (TH), snus or ultra-low machine yield tobacco-burning cigarettes (TB). *Statistically significant reduction (p<0.05) from week 0.
Figure 3.
Figure 3.
Percent change in urinary MHBMA, a marker of 1,3-butadiene exposure, over time in smokers switched to tobacco-heating cigarettes (TH), snus or ultra-low machine yield tobacco-burning cigarettes (TB). *Statistically significant reduction (p<0.05) from week 0.
Figure 4.
Figure 4.
Percent change in urinary HPMA, a marker of acrolein exposure, over time in smokers switched to tobacco-heating cigarettes (TH), snus or ultra-low machine yield tobacco-burning cigarettes (TB). *Statistically significantly different (p<0.05) from week 0.
Figure 5.
Figure 5.
Carboxyhemoglobin over time in smokers switched to tobacco-heating cigarettes (TH), snus or ultra-low machine yield tobacco-burning cigarettes (TB). *Statistically significant reduction (p < 0.05) from week 0.
Figure 6.
Figure 6.
4-Aminobiphenyl hemoglobin adducts over time in smokers switched to ultra-low machine yield tobacco-burning cigarettes (TB), tobacco-heating cigarettes (TH) or snus. *Statistically significant reduction (p < 0.05) from week 0.

References

    1. Adhikari B, Kahende J, Malarcher A, et al. Smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 2000–2004. MMWR. 2008;57:1226–8.
    1. Agency for Toxic Substances and Disease Registry (ATSDR). 2007.
    1. Benowitz NL, Dains KM, Hall SM, et al. Progressive commercial cigarette yield reduction: biochemical exposure and behavioral assessment. Cancer Epidemiol Biomarkers Prev. 2009;18:876–83.
    1. Bodnar JA, Morgan WT, Murphy PA, Ogden MW. Mainstream smoke chemistry analysis of samples from the 2009 US cigarette market. Regul Toxicol Pharmacol. 2012;64:35–42.
    1. Borgerding MF, Bodnar JA, Curtin GM, Swauger JE. The chemical composition of smokeless tobacco: a survey of products sold in the United States in 2006 and 2007. Regul Toxicol Pharmacol. 2012;64:367–87.
    1. Borgerding M, Klus H. Analysis of complex mixtures – cigarette smoke. Exp Toxicol Pathol. 2005;57:43–73.
    1. Byrd GD, Davis RA, Ogden MW. A rapid LC–MS–MS method for the determination of nicotine and cotinine in serum and saliva samples from smokers: validation and comparison with a radioimmunoassay method. J Chromatogr Sci. 2005;43:133–40.
    1. Byrd GD, Ogden MW. Liquid chromatographic/tandem mass spectrometric method for the determination of the tobacco-specific nitrosamine metabolite NNAL in smokers' urine. J Mass Spectrom. 2003;38:98–107.
    1. Carmella SG, Chen M, Han S, et al. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem Res Toxicol. 2009;22:734–41.
    1. Hatsukami DK, Benowitz NL, Rennard SI, et al. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res. 2006;8:600–22.
    1. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis. 2002;23:907–22.
    1. Hecht SS, Carmella SG, Le KA, et al. Effects of reduced cigarette smoking on levels of 1-hydroxypyrene in urine. Cancer Epidemiol Biomarkers Prev. 2004;13:834–42.
    1. International Agency for Research on Cancer (IARC). Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1–1452.
    1. International Conference on Harmonization (ICH). 1996.
    1. Joseph AM, Hecht SS, Murphy SE, et al. Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. Cancer Epidemiol Biomarkers Prev. 2005;14:2963–8.
    1. Kado NY, Langley D, Eisenstadt E. A simple modification of the Salmonella liquid-incubation assay. Increased sensitivity for detecting mutagens in human urine. Mutat Res. 1983;121:25–32.
    1. Kotlyar M, Hertsgaard LA, Lindgren BR, et al. Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. Cancer Epidemiol Biomarkers Prev. 2011;20:91–100.
    1. Lee PN. The effect of reducing the number of cigarettes smoked on risk of lung cancer, COPD, cardiovascular disease and FEV(1) – a review. Regul Toxicol Pharmacol. 2013;67:372–81.
    1. Lee EM, Malson JL, Moolchan ET, Pickworth WB. Quantitative comparisons between a nicotine delivery device (Eclipse) and conventional cigarette smoking. Nicotine Tob Res. 2004;6:95–102.
    1. Lewalter J, Gries W. Hemoglobin adducts for aromatic amines: aniline, o-, m-, p-toluidine, o-anisidine, p-chloroaniline, alpha- and beta-naphthylamine, 4-aminodiphenyl, benzidine, 4,4′-diaminodiphenylmethane, 3,3′-dichlorobenzidine. In: Angerer J, Schaller KH, editors. Analyses of hazardous substances in biological materials. Weinheim: Wiley-VCH; 2000. pp. 191–218.
    1. Leroy CM, Jarus-Dziedzic K, Ancerewica D, et al. Reduced exposure evaluation of an electrically heated cigarette system. Part 7: a one-month, randomized, ambulatory, controlled clinical study in Poland. Reg Tox Pharm. 2012;64:S74–84.
    1. Marano KM, Naufal ZS, Borgerding MB, Potts RJ. Quantitative risk assessment of tobacco-burning and tobacco-heating cigarettes. Rec Adv Tobacco Sci. 2012;38:3–20.
    1. Mascher DG, Mascher HJ, Scherer G, Schmid ER. High-performance liquid chromatographic-tandem mass spectrometric determination of 3-hydroxypropylmercapturic acid in human urine. J Chromatogr B Biomed Sci Appl. 2001;750:163–9.
    1. Meger M, Meger-Kossien I, Schuler-Metz A, et al. Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography–tandem mass spectrometry. J Chromatogr B. 2002;778:251–61.
    1. Mendes P, Kapur S, Wang J, et al. A randomized, controlled exposure study in adult smokers of full flavor Marlboro cigarettes switching to Marlboro Lights or Marlboro Ultra Lights cigarettes. Regul Toxicol Pharmacol. 2008;51:295–305.
    1. Nelson PR, Chen P, Dixon M, Steichen T. A survey of mouth level exposure to cigarette smoke in the United States. Regul Toxicol Pharmacol. 2011;61:S25–38.
    1. Nutt DJ, Phillips LD, Balfour D, et al. Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res. 2014;20:218–25.
    1. Ogden MW, Marano KM, Jones BA, et al. Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 3. Biomarkers of biological effect; 2015a.
    1. Ogden MW, Marano KM, Jones BA, Stiles MF. Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 1. Study design and methodology; 2015b.
    1. Richter E, Rösler S, Scherer G, et al. Haemoglobin adducts from aromatic amines in children in relation to area of residence and exposure to environmental tobacco smoke. Int Arch Occup Environ Health. 2001;74:421–8.
    1. Riedel K, Scherer G, Engl J, et al. Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers. J Anal Toxicol. 2006;30:187–95.
    1. Roethig HJ, Feng S, Liang Q, et al. A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. J Clin Pharmacol. 2008;48:580–91.
    1. Sarkar M, Liu J, Koval T, et al. Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro snus. Nicotine Tob Res. 2010;12:105–16.
    1. Scherer G, Frank S, Riedel K, et al. Biomonitoring of exposure to polycyclic aromatic hydrocarbons of nonoccupationally exposed persons. Cancer Epidemiol Biomarkers Prev. 2000a;9:373–80.
    1. Scherer G, Meger M, Meger-Kossien I, Pachinger A. Biological monitoring of the tobacco-smoke related exposure to acrolein. Proc Am Assoc Cancer Res. 2000b;42:150.
    1. Scherer G, Meger M, Meger-Kossien I, Pachinger A. Biological monitoring of the tobacco-smoke related exposure to benzene. Proc Am Assoc Cancer Res. 2001;41:146.
    1. Scherer G, Urban M, Hagedorn HW, et al. Determination of methyl-, 2-hydroxyethyl- and 2-cyanoethylmercapturic acids as biomarkers of exposure to alkylating agents in cigarette smoke. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2520–8.
    1. Sexton K. Biomarkers of toxicant exposure. In: DeCaprio AP, editor. Toxicologic biomarkers. New York: Taylor & Francis; 2006. pp. 39–62.
    1. Seyler TH, Bernert JT. Analysis of 4-aminobiphenyl in smoker's and nonsmoker's urine by tandem mass spectrometry. Biomarkers. 2011;16:212–21.
    1. Smith CJ, McKarns SC, Davis RA, et al. Human urine mutagenicity study comparing cigarettes which burn or primarily heat tobacco. Mutat Res. 1996;361:1–9.
    1. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: the science base for tobacco harm reduction-executive summary. Tob Control. 2001;10:189–95.
    1. Talaska G, Al-Zoughool M. Aromatic amines and biomarkers of human exposure. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2003;21:133–64.
    1. Uchida K, Kanematsu M, Sakai K, et al. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA. 1998;95:4882–7.
    1. US Department of Health and Human Services (USDHHS). Reducing the health consequences of smoking: 25 years of progress: a report of the surgeon general. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1989.
    1. US Department of Health and Human Services (USDHHS). The health consequences of smoking: a report of the surgeon general. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
    1. Urban M, Gilch G, Schepers G, et al. Determination of the major mercapturic acids of 1,3-butadiene in human and rat urine using liquid chromatography with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;796:131–40.
    1. Urban M, Kavvadias D, Riedel K, et al. Urinary mercapturic acids and a hemoglobin adduct for the dosimetry of acrylamide exposure in smokers and nonsmokers. Inhal Toxicol. 2006;18:831–9.
    1. US Congress . 2009.
    1. van Sittert NJ, Megens HJ, Watson WP, Boogaard PJ. Biomarkers of exposure to 1,3-butadiene as a basis for cancer risk assessment. Toxicol Sci. 2000;56:189–202.
    1. Wagner BM. Eclipse Expert Panel. A safer cigarette? A comparative study. A consensus report. Inhal Tox. 2000;12:1–48.
    1. Yang M, Koga M, Katoh T, Kawamoto T. A study for the proper application of urinary naphthols, new biomarkers for airborne polycyclic aromatic hydrocarbons. Arch Environ Contam Toxicol. 1999;36:99–108.
    1. Zeller M, Hatsukami D. Strategic Dialogue on Tobacco Harm Reduction Group. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control. 2009;18:324–32.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner